To catch up on all of the news from this past week, listen to our weekly news brief for the week of March 9–13, 2026.
This week’s brief covers an FDA Breakthrough Device Designation for a generative AI chest X-ray model, comparing AI tools scoring HER2 expression in breast cancer pathology, a computational histology platform predicting chemotherapy benefit in pancreatic cancer, and an MRI-based AI foundation predictive model in glioma.
To learn more about Cognita's Breakthrough Device Designation, read "Generative Vision-Language Radiology Model Gains FDA Breakthrough Device Designation."
For a comparison on HER2 expression level scorings, read "HER2 Scoring Interpretation Concordance Across Computational Pathology Models," or see the source report in Modern Pathology.
To learn more about the CHAI predictive platform, read "CHAI Biomarker for Chemotherapy Choice in Advanced Pancreatic Cancer," or see the source report in the Journal of Clinical Oncology.
For more information on an MRI-based AI foundation model, read "MRI-Based Foundation Model Predicts Key Molecular Biomarkers and Posttreatment Outcomes in Glioma," or see the source report in JCO Precision Oncology.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.